Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Rivastigmine
Advanz Pharma
N06DA03
Rivastigmine
13.3mg/24hour
Transdermal patch
Transdermal
No Controlled Drug Status
Valid as a prescribable product
BNF: 04110000; GTIN: 5060064792605
OBJECT 1 VOLEZE 13.3MG/24H TRANSDERMAL PATCH Summary of Product Characteristics Updated 16-Jan-2017 | Concordia International- formerly Focus Pharmaceuticals Ltd 1. Name of the medicinal product Voleze 13.3 mg/24 h transdermal patch 2. Qualitative and quantitative composition Each transdermal patch releases 13.3 mg rivastigmine per 24 hours. Each transdermal patch of 15 cm2 contains 27 mg rivastigmine. For the full list of excipients, see section 6.1. 3. Pharmaceutical form Transdermal patch. Round-shaped three-layer matrix transdermal patches. The outside of the backing layer is translucent, white and imprinted with black printing ink as follows: “Rivastigmine, 13.3 mg/24 h” 4. Clinical particulars 4.1 Therapeutic indications Symptomatic treatment of mild to moderately severe Alzheimer's dementia. 4.2 Posology and method of administration Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer's dementia. Diagnosis should be made according to current guidelines. Similar to any treatment initiated in patients with dementia, therapy with rivastigmine should only be started if a caregiver is available to regularly administer and monitor the treatment. Posology TRANSDERMAL PATCHES RIVASTIGMINE _IN VIVO _ RELEASE RATES PER 24 H Voleze 4.6 mg/24 h 4.6 mg* Voleze 9.5 mg/24 h 9.5 mg* Voleze 13.3 mg/24 h 13.3 mg* * For doses not realisable with this medicinal product other strengths of the medicinal product are available. _Initial dose_ Treatment is started with 4.6 mg/24 h. _Maintenance dose _ After a minimum of four weeks of treatment and if well tolerated according to the treating physician, the dose of 4.6 mg/24 h should be increased to 9.5 mg/24 h, the daily recommended effective dose, which should be continued for as long as the patient continues to demonstrate therapeutic benefit. _Dose escalation_ 9.5 mg/24 h is the recommended daily effective dose which should be continued for as long as the patient continues to demonstrate therapeutic benefit. If w Read the complete document